S
SanBio
A regenerative medicine company with cell-based products in various stages of research, development, and clinical trials
About SanBio
SanBio is a biotechnology company specializing in regenerative cell therapies aimed at treating neurological disorders and chronic diseases. Operating in the biopharmaceutical market, SanBio focuses on developing and commercializing advanced cell-based treatments. The company's flagship product, SB623, is designed to promote recovery in patients suffering from conditions such as stroke and traumatic brain injury. SanBio primarily serves patients, healthcare providers, and medical institutions. The business model revolves around research and development, clinical trials, and eventual commercialization of their cell therapy products. Revenue is generated through partnerships, licensing agreements, and direct sales of their therapies once approved.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2001
- Headquarters
- Tokyo, Japan
- Listing
- IPO 2015
- Employees
- 29
- Open positions
- 9
- Dealroom signal
- 58.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Regenerative Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Jun 2025 | $6.9M | — | Mizuho | ↗ |
| POST IPO DEBT✓Debt | Nov 2023 | $13M | — | Mizuho | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for SanBio is 11K monthly website visits, down 47.6% over the last three months. SanBio's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
SMBC Venture Capital
Mitsubishi UFJ Capital
California Institute for Regenerative Medicine
Series B and later1 investor entered at this stage
Mizuho
Other known investors4 additional known investors
Keio University
Medical Incubator Japan
Nissay Capital
Western Technology Investment
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about SanBio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SanBio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.